Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
Related Posts
![](https://static01.nyt.com/images/2024/03/19/multimedia/18anthropause-01-fcvk/18anthropause-01-fcvk-facebookJumbo.jpg)
Pandemic Lockdowns Had Varied Effects on Wildlife
Camera traps, which automatically snap photos of wild animals when they detect motion and body heat, have become key research…
![](https://static01.nyt.com/images/2023/12/26/multimedia/26SCI-SPAN-02-fglw/26SCI-SPAN-02-fglw-facebookJumbo.jpg)
This Gorilla’s Caregivers Face Familiar Questions About Aging
This month, as the patient lay anesthetized on a table, a cardiologist made a half-inch incision through the skin of…
![](https://static01.nyt.com/images/2024/04/03/multimedia/03parkinsons-mlbg/03parkinsons-mlbg-facebookJumbo.jpg)
An Ozempic Relative Slowed Parkinson’s Disease in a Small Study
In 1817, James Parkinson expressed a hope about the disease that is named after him. He thought that at some…